Origin & tradition
Berberine is the active alkaloid in Huang Lian (黄连) and related herbs, long used in Chinese medicine for digestive and heat-clearing applications.
Eastern tradition · Practitioner Supply
An alkaloid from Chinese herbs (Coptis / Huang Lian) with human RCTs on metabolic health and an AMPK/sirtuin longevity rationale.
Data definition. Matched records include all indexed medical endpoints for this intervention — not only longevity. Longevity-relevant records are screened separately and cited in the evidence summary below. Counts are matched-record volumes, not de-duplicated trials and not efficacy claims.
Berberine is the active alkaloid in Huang Lian (黄连) and related herbs, long used in Chinese medicine for digestive and heat-clearing applications.
Key active: Berberine (isoquinoline alkaloid).
Berberine activates AMPK — the same energy-sensing pathway as metformin — and is studied for SIRT1 activation and autophagy, with human RCTs on glucose, lipids and metabolic syndrome.
Effect summary
| Health outcome | Effect | Magnitude | Grade |
|---|---|---|---|
| Fasting blood glucose | Decreases | Strong | A |
| HbA1c | Decreases | Strong | A |
| LDL cholesterol | Decreases | Moderate | A |
| Triglycerides | Decreases | Moderate | A |
| Body weight | Decreases | Minor | B |
| AMPK activation | Increases | Strong | B |
| Gut microbiome diversity | Increases | Moderate | B |
Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data
Dosage guidance
Dihydroberberine (DHB) achieves comparable effects at ~100–200 mg with far better bioavailability. Do not combine with CYP3A4-metabolized drugs without medical supervision.
Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.
Evidence summary
Human RCTs (metabolic syndrome, NAFLD); mechanistic longevity rationale
Berberine activates AMPK — the same energy-sensing pathway as metformin — and is studied for SIRT1 activation and autophagy, with human RCTs on glucose, lipids and metabolic syndrome.
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed, compound data from EMBL-EBI ChEMBL. Counts auto-refresh weekly; last checked 2026-07-19. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.
Evidence collections
Compare the evidence
The diabetes drug at the center of the longevity debate — and the TAME trial designed to test aging itself.
The most-studied tea catechin, linked to lifespan and healthspan in models via AMPK, sirtuin and FOXO pathways.
A TCA-cycle metabolite that suppresses mTOR, co-factors DNA demethylation, and showed biological-age reduction in a 2023 human RCT.
“Southern ginseng,” a Chinese herb whose gypenosides activate AMPK — the metabolic longevity pathway.
Compare the evidence
Suppliers